JP2022553464A - 多重特異性抗体とその製造方法および使用 - Google Patents

多重特異性抗体とその製造方法および使用 Download PDF

Info

Publication number
JP2022553464A
JP2022553464A JP2021537127A JP2021537127A JP2022553464A JP 2022553464 A JP2022553464 A JP 2022553464A JP 2021537127 A JP2021537127 A JP 2021537127A JP 2021537127 A JP2021537127 A JP 2021537127A JP 2022553464 A JP2022553464 A JP 2022553464A
Authority
JP
Japan
Prior art keywords
antibody
binding
peptide linker
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553464A5 (cg-RX-API-DMAC10.html
Inventor
シン カオ
ニーリャン チエン
ホンチエ リー
ツイマー ヤン
フーユイ ワン
シウチエ パン
ユンホイ リョウ
トンメイ フー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2022553464A publication Critical patent/JP2022553464A/ja
Publication of JP2022553464A5 publication Critical patent/JP2022553464A5/ja
Priority to JP2025088503A priority Critical patent/JP2025143248A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021537127A 2019-10-24 2020-07-08 多重特異性抗体とその製造方法および使用 Pending JP2022553464A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025088503A JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911015236.1 2019-10-24
CN201911015236.1A CN110669137B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途
PCT/CN2020/100892 WO2021077806A1 (zh) 2019-10-24 2020-07-08 一种多特异性抗体及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025088503A Division JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Publications (2)

Publication Number Publication Date
JP2022553464A true JP2022553464A (ja) 2022-12-23
JP2022553464A5 JP2022553464A5 (cg-RX-API-DMAC10.html) 2023-07-19

Family

ID=69083964

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021537127A Pending JP2022553464A (ja) 2019-10-24 2020-07-08 多重特異性抗体とその製造方法および使用
JP2025088503A Pending JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025088503A Pending JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Country Status (7)

Country Link
US (2) US12415852B2 (cg-RX-API-DMAC10.html)
EP (1) EP3868788A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022553464A (cg-RX-API-DMAC10.html)
KR (1) KR20220087402A (cg-RX-API-DMAC10.html)
CN (2) CN110669137B (cg-RX-API-DMAC10.html)
AU (1) AU2020371001A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021077806A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
CN113214406B (zh) * 2020-01-21 2022-08-02 苏州普乐康医药科技有限公司 一种结合gpc3融合蛋白的制备方法及应用
CN112336873B (zh) 2020-08-04 2022-04-19 华南理工大学 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法
CN114478788B (zh) * 2020-11-11 2025-07-18 北京免疫方舟医药科技有限公司 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
CN115505041B (zh) * 2021-06-22 2026-05-05 北京免疫方舟医药科技有限公司 抗EphA2抗体及其应用
CN113527503A (zh) * 2021-07-27 2021-10-22 福建医科大学 一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白
CN118556083A (zh) * 2021-10-12 2024-08-27 乐普创一生物科技(上海)有限公司 具有改善的治疗指数的靶向cd3的t细胞衔接器
CN114409797B (zh) * 2021-12-24 2024-02-20 合肥天港免疫药物有限公司 重组抗体及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途
CN115368448B (zh) * 2022-07-19 2025-08-01 合肥天港免疫药物有限公司 双特异性抗体及其应用
US20260116960A1 (en) * 2022-09-29 2026-04-30 Shanghai Hongcheng Biopharmaceutical Co., Ltd. Trispecific antibodies targeting pd-1, ctla-4 and vegf and use thereof
CN115969997B (zh) * 2022-12-19 2024-02-13 华润生物医药有限公司 一种靶向cldn18.2的抗体药物偶联物及其应用
CN116987198B (zh) * 2023-09-28 2023-12-26 军科正源(北京)药物研究有限责任公司 一种靶向人pd-l1的融合蛋白及其用途
CN117843803B (zh) * 2023-12-29 2024-11-29 北京贝来药业有限公司 串联单域抗体及其在疾病治疗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131239A1 (ja) * 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
JP2010539921A (ja) * 2007-09-26 2010-12-24 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
JP2011516084A (ja) * 2008-04-11 2011-05-26 トルビオン・ファーマシューティカルズ・インコーポレイテッド Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
JP2018500315A (ja) * 2014-12-19 2018-01-11 アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. 組織石灰化の治療方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH07503124A (ja) * 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
CN100497390C (zh) * 2003-06-27 2009-06-10 比奥根艾迪克Ma公司 疏水-相互作用-层析或铰链区修饰对于均质抗体溶液的制备的用途
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
KR101886983B1 (ko) 2011-08-23 2018-08-08 로슈 글리카트 아게 2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2015103549A1 (en) * 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
CN107172880B (zh) * 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
KR20170017916A (ko) * 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
GB201409558D0 (en) * 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
CN104592392B (zh) * 2015-01-21 2018-08-28 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
AU2015366284B2 (en) * 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
CN104558191B (zh) * 2015-01-21 2020-08-21 武汉友芝友生物制药有限公司 一种双特异性抗体cd20×cd3的构建及应用
GB201521393D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
CN109563166B (zh) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
IL268995B2 (en) * 2017-03-02 2024-02-01 Nat Res Council Canada TGF-B receptor ectodomain fusion compounds and their uses
CN107266567B (zh) * 2017-06-05 2021-06-04 高新 Lcrmp4单克隆抗体及其制备方法与应用
AU2020283890A1 (en) * 2019-05-30 2021-12-16 Amgen Inc. Engineering the hinge region to drive antibody dimerization
CN110669137B (zh) 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539921A (ja) * 2007-09-26 2010-12-24 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
JP2011516084A (ja) * 2008-04-11 2011-05-26 トルビオン・ファーマシューティカルズ・インコーポレイテッド Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
WO2009131239A1 (ja) * 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
JP2018500315A (ja) * 2014-12-19 2018-01-11 アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. 組織石灰化の治療方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BREKKE OH. ET AL., IMMUNOL TODAY, vol. 16, JPN6025031559, 1995, pages 85 - 90, ISSN: 0005653431 *
DAVE E. ET AL., MABS, vol. 8, JPN6024028389, 2016, pages 1319 - 1335, ISSN: 0005373907 *
IMGT SCIENTIFIC CHART[ONLINE], JPN6025002338, 20 October 2019 (2019-10-20), ISSN: 0005653430 *

Also Published As

Publication number Publication date
AU2020371001A1 (en) 2021-06-10
CN113416258A (zh) 2021-09-21
US12415852B2 (en) 2025-09-16
WO2021077806A1 (zh) 2021-04-29
US20210388077A1 (en) 2021-12-16
EP3868788A1 (en) 2021-08-25
CN110669137B (zh) 2021-07-16
CN110669137A (zh) 2020-01-10
US20260001947A1 (en) 2026-01-01
KR20220087402A (ko) 2022-06-24
EP3868788A4 (en) 2022-08-24
JP2025143248A (ja) 2025-10-01
CN113416258B (zh) 2023-08-29

Similar Documents

Publication Publication Date Title
JP2025143248A (ja) 多重特異性抗体とその製造方法および使用
US12384842B2 (en) Antibody molecules that bind to NKP30 and uses thereof
JP2022553464A5 (cg-RX-API-DMAC10.html)
TW202012441A (zh) Nk細胞接合抗體融合構築體
US20230348593A1 (en) Antibody molecules that bind to nkp30 and uses thereof
MX2014000816A (es) Molecula fv de union de antigeno multivalente.
JP2018522564A (ja) 抗グリピカン3抗体およびその使用
JP7809639B2 (ja) Mait及び腫瘍細胞の両方に結合する多重特異性抗体
WO2022222910A1 (zh) 靶向gprc5d的抗体及其用途
IL304898A (en) New anti-CD24 antibodies
CN106831995A (zh) 新型双特异性抗体及其用途
JP2025542327A (ja) 新規抗gprc5d抗体
US20250381223A1 (en) Humanized anti-cd28 antibody and bispecific antibody thereof with anti-cd40 antibody
WO2022100652A1 (zh) 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
WO2024027120A1 (en) Multi-specific polypeptide complexes
RU2774711C2 (ru) Слитые конструкции антител для вовлечения nk-клеток
TW202413431A (zh) 抗taa和cd3的多特異性抗體
JP2025542322A (ja) Gprc5dを標的とする多重特異性ポリペプチド複合物
HK40090244A (en) Multispecific antibodies that bind both mait and tumor cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250128

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250527